--- title: "UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline" type: "News" locale: "en" url: "https://longbridge.com/en/news/285030926.md" description: "United Community Banks, Inc. (UCB) has agreed to acquire Candel Therapeutics, Inc. (CADL) for up to $2.2 billion to enhance its immunology pipeline. The deal, which includes $2 billion upfront and up to $200 million based on future milestones, is expected to close between late Q2 and early Q3 of 2026. UCB anticipates manageable financial impact and steady growth in revenue and profit. Candel's main drug, cizutamig, is in Phase 1 trials for autoimmune diseases. UCB's stock rose 0.57% to $33.52, while Candel's stock increased 4.69% to $6.47." datetime: "2026-05-04T05:30:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285030926.md) - [en](https://longbridge.com/en/news/285030926.md) - [zh-HK](https://longbridge.com/zh-HK/news/285030926.md) --- # UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline Add as your preferred news source on Google Add Now United Community Banks, Inc. (UCB),on Sunday agreed to buy Candel Therapeutics, Inc. (CADL) for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related diseases. The deal is expected to close between late second quarter and early third quarter of 2026. The deal includes $2 billion paid upfront and up to $200 million tied to future milestones. The acquisition helps UCB expand its work in next-generation biologic drugs and improve treatments for conditions where the immune system attacks the body. UCB said the financial impact will be manageable, and its 2026 outlook remains unchanged, with steady revenue and profit growth expected. Candid's main drug, cizutamig, is an early-stage treatment designed to help the immune system target harmful cells. It is currently being tested in several Phase 1 studies for autoimmune diseases. On Friday, UCB closed trading 0.57% higher at $33.52 on the New York Stock Exchange. On Friday, Candel Therapeutics closed trading 4.69% higher at $6.47 on the Nasdaq. In the overnight, the stock further traded 3.40% higher at $6.69, 0.22 cents up. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [CADL.US](https://longbridge.com/en/quote/CADL.US.md) - [UCB.US](https://longbridge.com/en/quote/UCB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [UCB.PRI.US](https://longbridge.com/en/quote/UCB.PRI.US.md) - [UCB-I.US](https://longbridge.com/en/quote/UCB-I.US.md) ## Related News & Research - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [UCB reports positive outcomes for bimekizumab in psoriatic arthritis](https://longbridge.com/en/news/286906544.md) - [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results](https://longbridge.com/en/news/286319406.md)